Loading…
Data as of .
| Market | Companies | Market cap | 6M (cap-wt) | Median revenue growth |
|---|---|---|---|---|
| United States | 468 | $8.52T | +30.0% | +10% |
| Switzerland | 29 | $971B | +21.3% | +1% |
| China | 432 | $913B | -0.9% | +2% |
| United Kingdom | 13 | $463B | +1.9% | +3% |
| Hong Kong | 110 | $458B | +2.2% | +16% |
| Japan | 69 | $454B | +4.0% | +7% |
| India | 102 | $390B | +18.0% | +20% |
| France | 18 | $287B | +12.8% | +2% |
| Germany | 21 | $280B | +30.2% | +3% |
| Denmark | 11 | $279B | +15.0% | +6% |
| South Korea | 57 | $165B | -10.8% | +11% |
| Australia | 18 | $142B | +63.4% | +9% |
| Sweden | 22 | $59.8B | +23.7% | +4% |
| Taiwan | 36 | $41.3B | +64.6% | +5% |
| Netherlands | 3 | $32.9B | +23.2% | +2% |
| Italy | 8 | $25.4B | +7.7% | +3% |
| Canada | 10 | $24.1B | +25.3% | +16% |
| Spain | 6 | $18.1B | +10.1% | +18% |
| Finland | 3 | $17.4B | +44.9% | +16% |
| Singapore | 5 | $5.12B | -19.6% | -3% |
| Poland | 4 | $3.23B | +7.8% | +17% |
| Norway | 2 | $904M | +15.1% | +19% |
| Company | Market | Industry | Market cap | 1M | 6M | Revenue growth | Op. margin | Fwd P/E |
|---|---|---|---|---|---|---|---|---|
| Lilly (Eli) LLY | United States | Pharmaceuticals: Major | $1.27T | +16% | +43% | +46% | 51% | 28.9× |
| Johnson & Johnson JNJ | United States | Pharmaceuticals: Major | $665B | +8% | +26% | +8% | 26% | 24.5× |
| AbbVie ABBV | United States | Pharmaceuticals: Major | $515B | +7% | +45% | +11% | 36% | 18.4× |
| Roche RO.SW | Switzerland | Pharmaceuticals: Major | $385B | +11% | +22% | -1% | 31% | 19.6× |
| Merck & MRK | United States | Pharmaceuticals: Major | $362B | +3% | +33% | +5% | 18% | 17.4× |
| UnitedHealth UNH | United States | Managed Health Care | $353B | +6% | +4% | +3% | 5% | 17.4× |
| Novartis NOVN.SW | Switzerland | Pharmaceuticals: Major | $298B | +13% | +15% | -4% | 30% | 18.4× |
| AstraZeneca AZN.L | United Kingdom | Pharmaceuticals: Major | $291B | +17% | +1% | +5% | 23% | 18.3× |
| Thermo Fisher Scientific TMO | United States | Medical Specialties | $257B | +7% | +50% | +8% | 19% | 25.8× |
| Amgen AMGN | United States | Biotechnology | $249B | +13% | +40% | +9% | 36% | 18.9× |
| Gilead Sciences GILD | United States | Biotechnology | $207B | +13% | +28% | +7% | 38% | 19.3× |
| Abbott Laboratories ABT | United States | Medical Specialties | $190B | +12% | +30% | +10% | 14% | 18.8× |
| Novo Nordisk A/S NOVO-B.CO | Denmark | Pharmaceuticals: Major | $190B | +8% | -7% | +6% | 48% | 11.9× |
| Pfizer PFE | United States | Pharmaceuticals: Major | $168B | +6% | +14% | +1% | 26% | 10.4× |
| Danaher DHR | United States | Medical Specialties | $162B | +6% | +35% | +6% | 21% | 25.3× |
| Intuitive Surgical ISRG | United States | Medical Specialties | $157B | +9% | +1% | +20% | 32% | 37.5× |
| Vertex Pharmaceuticals VRTX | United States | Pharmaceuticals: Major | $139B | +9% | +27% | +11% | 35% | 29.0× |
| Medtronic MDT | United States | Medical Specialties | $130B | +16% | +35% | +10% | 20% | 16.9× |
| Bristol Myers Squibb BMY | United States | Pharmaceuticals: Major | $127B | +4% | +12% | +4% | 33% | 9.7× |
| Stryker SYK | United States | Medical Specialties | $124B | +18% | +14% | +8% | 25% | 20.4× |
| McKesson MCK | United States | Medical Distributors | $124B | +14% | +44% | +9% | 2% | 21.8× |
| Sanofi SAN.PA | France | Pharmaceuticals: Major | $113B | +18% | +14% | +15% | 27% | 9.6× |
| CVS Health CVS | United States | Drugstore Chains | $107B | -4% | -7% | +7% | 4% | 9.9× |
| HCA Healthcare HCA | United States | Hospital/Nursing Management | $103B | +11% | +14% | +6% | 15% | 16.2× |
| GSK GSK.L | United Kingdom | Pharmaceuticals: Major | $102B | +9% | 0% | +4% | 25% | 10.6× |
| Moderna MRNA | United States | Biotechnology | $101B | +3% | +43% | -28% | -149% | n/a |
| EssilorLuxottica EL.PA | France | Medical Specialties | $101B | +36% | +12% | +8% | 12% | 26.6× |
| Regeneron Pharmaceuticals REGN | United States | Pharmaceuticals: Major | $93.5B | +22% | +27% | +19% | 30% | 11.3× |
| Elevance Health ELV | United States | Managed Health Care | $92.0B | +6% | +13% | +4% | 4% | 14.8× |
| Cigna CI | United States | Managed Health Care | $77.6B | +4% | +3% | +8% | 4% | 9.0× |
| Merck KGaA MRK.DE | Germany | Pharmaceuticals: Major | $72.5B | +10% | +23% | 0% | 20% | 17.5× |
| Chugai Pharmaceutical 4519.T | Japan | Pharmaceuticals: Major | $71.0B | +11% | -15% | +17% | 50% | 22.1× |
| CSL CSL.AX | Australia | Biotechnology | $67.2B | +11% | +105% | -2% | 26% | 22.4× |
| WuXi AppTec 603259.SS | China | Pharmaceuticals: Major | $67.0B | -9% | +34% | +32% | 43% | 18.1× |
| Takeda Pharmaceutical 4502.T | Japan | Pharmaceuticals: Major | $66.4B | +15% | +24% | +6% | 18% | 42.1× |
| Wuxi Apptec 2359.HK | Hong Kong | Pharmaceuticals: Major | $66.3B | -11% | +40% | +38% | 44% | 20.4× |
| Cencora COR | United States | Medical Distributors | $63.7B | +4% | +28% | +5% | 1% | 16.9× |
| Cardinal Health CAH | United States | Medical Distributors | $62.9B | +14% | +48% | +14% | 1% | 20.8× |
| Boston Scientific BSX | United States | Medical Specialties | $62.0B | +2% | -21% | +9% | 21% | 13.8× |
| Bayer BAYN.DE | Germany | Pharmaceuticals: Major | $61.2B | +30% | +46% | -2% | 14% | 12.3× |
| Edwards Lifesciences EW | United States | Medical Specialties | $58.9B | +21% | +28% | +15% | 29% | 31.4× |
| Becton Dickinson BDX | United States | Medical Specialties | $57.7B | +16% | +43% | -3% | 15% | 16.0× |
| argenx SE Sponsored ADR ARGX | United States | Biotechnology | $57.5B | +13% | +19% | +71% | 29% | n/a |
| Siemens Healthineers SHL.DE | Germany | Medical Specialties | $55.9B | +17% | +31% | -1% | 15% | 18.9× |
| Lonza LONN.SW | Switzerland | Biotechnology | $55.4B | +18% | +39% | -11% | 25% | 36.1× |
| Galderma GALD.SW | Switzerland | Pharmaceuticals: Major | $54.8B | +18% | +17% | +16% | 19% | 48.1× |
| Samsung Biologics 207940.KS | South Korea | Biotechnology | $53.7B | +19% | +3% | -20% | 43% | 38.7× |
| Idexx Laboratories IDXX | United States | Medical Specialties | $53.3B | +32% | +21% | +12% | 32% | 41.5× |
| Medline MDLN | United States | Medical Specialties | $52.1B | +11% | 0% | +12% | 6% | 26.1× |
| Humana HUM | United States | Managed Health Care | $52.1B | +12% | +58% | +18% | 2% | 32.9× |